BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 20662002)

  • 1. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma.
    Doyle B; Morton JP; Delaney DW; Ridgway RA; Wilkins JA; Sansom OJ
    J Pathol; 2010 Oct; 222(2):129-37. PubMed ID: 20662002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. You can win by losing: p53 mutations in rhabdomyosarcomas.
    Post SM; Lozano G
    J Pathol; 2010 Oct; 222(2):124-8. PubMed ID: 20821751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer.
    Morton JP; Timpson P; Karim SA; Ridgway RA; Athineos D; Doyle B; Jamieson NB; Oien KA; Lowy AM; Brunton VG; Frame MC; Evans TR; Sansom OJ
    Proc Natl Acad Sci U S A; 2010 Jan; 107(1):246-51. PubMed ID: 20018721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice.
    Nanni P; Nicoletti G; De Giovanni C; Croci S; Astolfi A; Landuzzi L; Di Carlo E; Iezzi M; Musiani P; Lollini PL
    Cancer Res; 2003 Jun; 63(11):2728-32. PubMed ID: 12782574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse Models of Human Gastric Cancer Subtypes With Stomach-Specific CreERT2-Mediated Pathway Alterations.
    Seidlitz T; Chen YT; Uhlemann H; Schölch S; Kochall S; Merker SR; Klimova A; Hennig A; Schweitzer C; Pape K; Baretton GB; Welsch T; Aust DE; Weitz J; Koo BK; Stange DE
    Gastroenterology; 2019 Dec; 157(6):1599-1614.e2. PubMed ID: 31585123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
    Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
    Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras.
    Acin S; Li Z; Mejia O; Roop DR; El-Naggar AK; Caulin C
    J Pathol; 2011 Dec; 225(4):479-89. PubMed ID: 21952947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of mouse models of angiosarcoma driven by p53.
    Salter DM; Griffin M; Muir M; Teo K; Culley J; Smith JR; Gomez-Cuadrado L; Matchett K; Sims AH; Hayward L; Henderson NC; Brunton VG
    Dis Model Mech; 2019 Jul; 12(7):. PubMed ID: 31221668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The p53 tumor suppressor gene and gene product.
    Levine AJ
    Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transgenic mouse model expressing P53(R172H), luciferase, EGFP, and KRAS(G12D) in a single open reading frame for live imaging of tumor.
    Ju HL; Calvisi DF; Moon H; Baek S; Ribback S; Dombrowski F; Cho KJ; Chung SI; Han KH; Ro SW
    Sci Rep; 2015 Jan; 5():8053. PubMed ID: 25623590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.
    Ianzano ML; Croci S; Nicoletti G; Palladini A; Landuzzi L; Grosso V; Ranieri D; Dall'Ora M; Santeramo I; Urbini M; De Giovanni C; Lollini PL; Nanni P
    Oncotarget; 2014 Jan; 5(1):108-19. PubMed ID: 24334679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.
    Westcott PM; Halliwill KD; To MD; Rashid M; Rust AG; Keane TM; Delrosario R; Jen KY; Gurley KE; Kemp CJ; Fredlund E; Quigley DA; Adams DJ; Balmain A
    Nature; 2015 Jan; 517(7535):489-92. PubMed ID: 25363767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma.
    Mohamed AD; Shah N; Hettmer S; Vargesson N; Wackerhage H
    Sci Rep; 2018 Oct; 8(1):15674. PubMed ID: 30353028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer.
    Miller P; Akama-Garren EH; Owen RP; Demetriou C; Carroll TM; Slee E; Al Moussawi K; Ellis M; Goldin R; O'Neill E; Lu X
    Cell Death Differ; 2023 Jul; 30(7):1619-1635. PubMed ID: 37270580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.
    Kasinski AL; Slack FJ
    Cancer Res; 2012 Nov; 72(21):5576-87. PubMed ID: 22964582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma.
    Takahashi Y; Oda Y; Kawaguchi K; Tamiya S; Yamamoto H; Suita S; Tsuneyoshi M
    Mod Pathol; 2004 Jun; 17(6):660-9. PubMed ID: 15098008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo.
    Comiskey DF; Jacob AG; Sanford BL; Montes M; Goodwin AK; Steiner H; Matsa E; Tapia-Santos AS; Bebee TW; Grieves J; La Perle K; Boyaka P; Chandler DS
    Oncogene; 2018 Jan; 37(1):95-106. PubMed ID: 28892044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a novel experimental system using single cell-derived pleomorphic rhabdomyosarcoma cell lines expressing K-RasG12V and deficient in p53.
    Saito H; Suzuki N
    Exp Anim; 2023 Nov; 72(4):446-453. PubMed ID: 37081671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Point mutations of N-ras oncogene and abnormal expression of rasp21, p53 proteins in orbital rhabdomyosarcoma].
    Zhang H; Song G; Zhang S; Chang J; Zhang W; Yu H
    Zhonghua Yan Ke Za Zhi; 2000 Jul; 36(4):267-9, 16. PubMed ID: 11853610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice.
    Jiang D; Dumur CI; Massey HD; Ramakrishnan V; Subler MA; Windle JJ
    PLoS One; 2015; 10(2):e0118029. PubMed ID: 25695772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.